Manal F Abdelmalek

List of Publications by Year in Descending Order

136 papers	13,278 citations	58 h-index	114 g-index
145 ext. papers	17,308 ext. citations	8.1 avg, IF	6.24 L-index

#	Paper	IF	Citations
136	Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children.. *Epigenetics*, **2022**, 1-16	5.7	1
135	Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.. *The Lancet Gastroenterology and Hepatology*, **2022**,	18.8	3
134	Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.. *PLoS ONE*, **2022**, 17, e0266859	3.7	0
133	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. *American Journal of Gastroenterology*, **2021**, 116, 254-262	0.7	20
132	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. *JACC Basic To Translational Science*, **2021**, 6, 918-932	8.7	6
131	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. *New England Journal of Medicine*, **2021**, 385, 1547-1558	59.2	50
130	Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. *Hepatology*, **2021**,	11.2	7
129	The role of bariatric surgery in the management of nonalcoholic steatohepatitis. *Current Opinion in Gastroenterology*, **2021**, 37, 208-215	3	2
128	The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. *Contemporary Clinical Trials*, **2021**, 104, 106335	2.3	9
127	Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. *Hepatology*, **2021**, 74, 1220-1233	11.2	12
126	Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1267-1274.e1	6.9	4
125	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 24-39	24.2	67
124	REPLY. *Hepatology*, **2021**, 73, 1625	11.2	
123	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. *Journal of Hepatology*, **2021**, 74, 274-282	13.4	12
122	Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations. *Hepatology*, **2021**, 73, 1199-1206	11.2	9
121	Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis. *Translational Gastroenterology and Hepatology*, **2021**, 6, 13	5.2	5
120	Insights Into Metabolic Mechanisms and Their Application in the Treatment of NASH. *Clinical Liver Disease*, **2021**, 17, 29-32	2.2	1

119	Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. *Hepatology Communications*, **2021**, 5, 608-617	6	3
118	Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. *ESC Heart Failure*, **2021**, 8, 842-848	3.7	7
117	Epithelia-Sensory Neuron Cross Talk Underlies Cholestatic Itch Induced by Lysophosphatidylcholine. *Gastroenterology*, **2021**, 161, 301-317.e16	13.3	18
116	A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. *Hepatology*, **2021**, 74, 3146-3160	11.2	1
115	Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease. *Journal of Hepatology*, **2021**, 75, 623-633	13.4	7
114	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*, **2021**, 161, 1657-1669	13.3	17
113	Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD. *Hepatology Communications*, **2021**, 5, 598-607	6	2
112	Nonalcoholic fatty liver disease: another leap forward. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 85-86	24.2	18
111	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology*, **2020**, 158, 1999-2014.e1	13.3	748
110	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. *Hepatology*, **2020**, 72, 892-905	11.2	116
109	Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. *Hepatology*, **2020**, 72, 1219-1229	11.2	39
108	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. *Journal of Hepatology*, **2020**, 73, 680-693	13.4	32
107	Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. *Liver Transplantation*, **2020**, 26, 68-79	4.5	8
106	Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation. *Liver International*, **2020**, 40, 830-843	7.9	14
105	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. *Contemporary Clinical Trials*, **2020**, 89, 105922	2.3	49
104	Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. *Cellular and Molecular Gastroenterology and Hepatology*, **2020**, 10, 1-21	7.9	20
103	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. *Journal of Hepatology*, **2020**, 72, 885-895	13.4	65
102	Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. *Gastroenterology*, **2020**, 158, 1334-1345.e5	13.3	105

101	PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. *Molecular Metabolism*, **2019**, 29, 99-113	8.8	11
100	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. *Hepatology*, **2019**, 70, 1913-1927	11.2	111
99	Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 1867-1876.e3	6.9	16
98	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 1877-1885.e5	6.9	63
97	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. *Hepatology*, **2019**, 70, 1457-1469	11.2	238
96	Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. *Digestive Diseases and Sciences*, **2019**, 64, 3413-3430	4	5
95	Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury. *Journal of Clinical Investigation*, **2019**, 129, 5278-5293	15.9	13
94	A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. *Hepatology Communications*, **2019**, 3, 1571-1584	6	8
93	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet, The*, **2019**, 394, 2184-2196	40	425
92	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. *American Journal of Gastroenterology*, **2019**, 114, 1626-1635	0.7	34
91	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 156-163.e2	6.9	149
90	Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. *Journal of Hepatology*, **2019**, 70, 735-744	13.4	42
89	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. *Gastroenterology*, **2019**, 156, 88-95.e5	13.3	39
88	Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. *Journal of Hepatology*, **2019**, 70, 133-141	13.4	101
87	Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. *Liver International*, **2019**, 39, 924-932	7.9	31
86	Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. *Lancet, The*, **2019**, 392, 2705-2717	40	227
85	NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet, The*, **2018**, 391, 1174-1185	40	256
84	Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. *Journal of Hepatology*, **2018**, 68, 1063-1075	13.4	346

83	Reply. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1684	6.9	
82	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. *Hepatology*, **2018**, 67, 2001-2012	11.2	79
81	Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. *Hepatology*, **2018**, 67, 134-144	11.2	124
80	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. *Hepatology*, **2018**, 67, 1754-1767	11.2	376
79	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. *Hepatology*, **2018**, 68, 1646-1648	11.2	1
78	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. *Journal of Hepatology*, **2018**, 69, 1365-1370	13.4	29
77	Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Hepatology Communications*, **2018**, 2, 1344-1355	6	34
76	Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study. *PLoS ONE*, **2018**, 13, e0204308	3.7	8
75	Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis. *Gastroenterology*, **2018**, 155, 1428-1435.e2	13.3	34
74	Whole-Exome Sequencing Study of Extreme Phenotypes of NAFLD. *Hepatology Communications*, **2018**, 2, 1021-1029	6	4
73	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. *Gastroenterology*, **2018**, 155, 1140-1153	13.3	156
72	De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. *Clinics in Liver Disease*, **2017**, 21, 321-335	4.6	13
71	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. *Journal of Pediatrics*, **2017**, 187, 141-146.e1	3.6	64
70	Reply to Kim et al. *American Journal of Gastroenterology*, **2017**, 112, 807-808	0.7	
69	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 127-131.e2	6.9	38
68	Exercise Training as Treatment of Nonalcoholic Fatty Liver Disease. *Journal of Functional Morphology and Kinesiology*, **2017**, 2, 35	2.4	6
67	Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis. *American Journal of Gastroenterology*, **2016**, 111, 1591-1598	0.7	30
66	NAFLD: The clinical and economic burden of NAFLD: time to turn the tide. *Nature Reviews Gastroenterology and Hepatology*, **2016**, 13, 685-686	24.2	11

65	A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. *Hepatology*, **2016**, 64, 85-91	11.2	87
64	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-□and□□Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. *Gastroenterology*, **2016**, 150, 1147-1159.e5	13.3	629
63	Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers. *Journal of Pathology*, **2016**, 238, 531-42	9.4	25
62	Nonalcoholic Fatty Liver Disease. *North Carolina Medical Journal*, **2016**, 77, 216-9	0.6	3
61	Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging. *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control*, **2015**, 62, 165-75	3.2	93
60	Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver. *Ultrasound in Medicine and Biology*, **2015**, 41, 1948-57	3.5	24
59	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet, The*, **2015**, 385, 956-65	40	1421
58	Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. *Hepatology*, **2015**, 61, 98-107	11.2	51
57	Reply: To PMID 24849310. *Hepatology*, **2015**, 61, 1770-1	11.2	
56	Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. *Hepatology*, **2014**, 59, 471-82	11.2	188
55	No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. *Gastroenterology*, **2014**, 147, 377-84.e1	13.3	212
54	Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. *Endocrinology*, **2014**, 155, 4591-601	4.8	29
53	Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. *Hepatology*, **2014**, 59, 1406-14	11.2	162
52	Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. *Gastroenterology*, **2013**, 145, 1076-87	13.3	248
51	IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients. *Journal of Hepatology*, **2013**, 58, 402-3	13.4	11
50	High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. *Hepatology*, **2013**, 58, 1632-43	11.2	177
49	Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. *FASEB Journal*, **2013**, 27, 1674-89	0.9	32
48	Hedgehog pathway and pediatric nonalcoholic fatty liver disease. *Hepatology*, **2013**, 57, 1814-25	11.2	46

47	Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. *Liver International*, **2013**, 33, 1062-70	7.9	85
46	Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. *American Journal of Transplantation*, **2012**, 12, 694-705	8.7	80
45	A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. *Hepatology*, **2012**, 55, 419-28	11.2	127
44	Association between puberty and features of nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 786-94	6.9	44
43	Reply to: The use of acoustic radiation force-based shear stiffness in non-alcoholic fatty liver disease. *Journal of Hepatology*, **2012**, 56, 996	13.4	4
42	Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. *Human Pathology*, **2012**, 43, 790-800	3.7	55
41	Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. *Hepatology*, **2012**, 55, 1711-21	11.2	143
40	Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. *Hepatology*, **2012**, 56, 952-60	11.2	125
39	NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. *Gut*, **2012**, 61, 1323-9	19.2	181
38	Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. *Journal of Hepatology*, **2011**, 55, 666-672	13.4	264
37	Increased production of sonic hedgehog by ballooned hepatocytes. *Journal of Pathology*, **2011**, 224, 401-10	5.4	113
36	Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. *Hepatology*, **2011**, 53, 106-15	11.2	182
35	Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 1062-9	6.9	16
34	Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. *European Journal of Nutrition*, **2010**, 49, 1-9	5.2	72
33	Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. *Hepatology*, **2010**, 51, 1961-71	11.2	479
32	Reply: Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?. *Hepatology*, **2010**, 51, 1859-1860	11.2	2
31	Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. *Hepatology*, **2009**, 50, 1818-26	11.2	151
30	Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. *Gastroenterology*, **2009**, 137, 1478-1488.e8	13.3	204

29	Nonalcoholic fatty liver disease in women. *Womens Health*, **2009**, 5, 191-203	3	95
28	Fructose consumption as a risk factor for non-alcoholic fatty liver disease. *Journal of Hepatology*, **2008**, 48, 993-9	13.4	597
27	Acute liver failure occurring immediately following anti-D immune globulin infusion in a patient with chronic hepatitis B infection. *Digestive Diseases and Sciences*, **2007**, 52, 914-9	4	2
26	The impact of steatosis and alcohol on hepatitis C. *Current Hepatitis Reports*, **2007**, 6, 39-45		
25	Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. *American Journal of Gastroenterology*, **2007**, 102, 1333-4	0.7	22
24	Nonalcoholic fatty liver disease as a complication of insulin resistance. *Medical Clinics of North America*, **2007**, 91, 1125-49, ix	7	117
23	Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. *Liver Transplantation*, **2006**, 12, 51-7	4.5	131
22	Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation. *Liver Transplantation*, **2006**, 12, 754-61	4.5	29
21	Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis. *Liver Transplantation*, **2006**, 12, 306-9	4.5	8
20	Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology*, **2006**, 4, 1162-9	6.9	58
19	Mechanisms underlying nonalcoholic steatohepatitis. *Drug Discovery Today Disease Mechanisms*, **2006**, 3, 479-488		8
18	Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation. *Digestive Diseases and Sciences*, **2006**, 51, 1226-9	4	13
17	Short recovery time after percutaneous liver biopsy: should we change our current practices?. *Clinical Gastroenterology and Hepatology*, **2005**, 3, 926-9	6.9	74
16	A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. *American Journal of Transplantation*, **2005**, 5, 1111-9	8.7	78
15	Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. *Liver Transplantation*, **2004**, 10, 199-207	4.5	123
14	One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. *Liver Transplantation*, **2004**, 10, 1240-7	4.5	133
13	Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient. *Transplantation*, **2003**, 75, 730-2	1.8	11
12	Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. *Liver Transplantation*, **2003**, 9, 1253-1257	4.5	32

11	Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. *Hepatology*, **2003**, 38, 859-68	11.2	104
10	Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. *Liver Transplantation*, **2002**, 8, 1000-6	4.5	105
9	Tropheryma whippelii DNA is rare in the intestinal mucosa of patients without other evidence of Whipple disease. *Annals of Internal Medicine*, **2001**, 134, 115-9	8	72
8	Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. *Liver Transplantation*, **2001**, 7, 1064-70	4.5	120
7	Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. *American Journal of Gastroenterology*, **2001**, 96, 2711-7	0.7	322
6	Whipple's arthritis: direct detection of Tropheryma whippelii in synovial fluid and tissue. *Arthritis and Rheumatism*, **1999**, 42, 812-7		96
5	Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. *Journal of Clinical Gastroenterology*, **1998**, 26, 130-4	3	16
4	Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. *Digestive Diseases and Sciences*, **1997**, 42, 847-50	4	25
3	Rectal bleeding from a mucous fistula secondary to a Dieulafoy's lesion. *Journal of Clinical Gastroenterology*, **1997**, 24, 259-61	3	10
2	79-year-old woman with blue toes. *Mayo Clinic Proceedings*, **1995**, 70, 292-5	6.4	7
1	Two cases from the spectrum of nonalcoholic steatohepatitis. *Journal of Clinical Gastroenterology*, **1995**, 20, 127-30	3	92